CALVANI et al. U.S. National Phase of PCT/IT2003/000566

AMENDMENT TO THE ABSTRACT

Please substitute the current Abstract of the Disclosure with the one that is on the attached sheet.

CALVANI et al. U.S. National Phase of PCT/IT2003/000566

ABSTRACT OF THE DISCLOSURE

Propionyl L-carnitine is used for the treatment of glaucoma and is preferably administrated orally or ophthalmically. Propionyl L-carnitine exhibits an anti-aptoptotic action on the nerve cells of the eye.